Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (ChiCTR2600132818) titled 'Adebrelimab in Combination with Apatinib and Systemic Chemotherapy for Initially Unresectable Biliary Tract Cancer:A Single-Arm, Multicenter, Exploratory Study' on Sept. 18.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Condition:
Intrahepatic cholangiocarcinoma
hilar cholangiocarcinoma, distal cholangiocarcinoma
gallbladder cancer.
Intervention:
Treatment group:Treatment period: Adebrelimab 1200mg, intravenous infusion, Day 1, every 21 days as one cycle
Gemcitabine 1000 mg/m2, intravenous i...